Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in IgE-mediated Food Allergy
NCT07768371Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in IgE-mediated food allergy, peanut allergy, cow's milk allergy (CMA) and 1 more (8 arms), sponsored by Novartis. Primary endpoints: Number of participants achieving response status (tolerated at least 600 mg of peanut protein) at 24 weeks, Number of participants achieving response status (tolerated at least 1000 mg of milk protein) at 24 weeks and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
IgE-mediated food allergypeanut allergycow's milk allergy (CMA)egg allergy
Beyond the preview
Go deeper on NCT07768371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768371.